FAPP2 GLTP Domain Crystal Structure for Fabry Disease Inhibitor Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy, have limitations, and there is a need for alternative strategies like substrate reduction therapy that target the FAPP2 protein to reduce Gb3 accumulation, but specific inhibitors for FAPP2 are not available due to the lack of a high-resolution crystal structure of its GLTP domain.
Innovation Solution
A high-resolution crystal structure of the GLTP domain of FAPP2 has been generated, allowing for the design and optimization of inhibitors by providing atomic-level structural information and enabling the identification of compounds that bind to FAPP2, which can reduce Gb3 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Fabry disease, then galactosidase activity is delivered to lysosomes to reduce Gb3 accumulation, but the treatment has limitations and does not provide a complete cure
Solution Approach 1:
The patent uses FAPP2 as an intermediary target in the substrate reduction therapy approach. Instead of directly replacing the deficient enzyme, the invention targets FAPP2 (a transfer protein) as a mediator that controls the availability of GlcCer substrate for Gb3 synthesis. By inhibiting FAPP2, the pathway leading to Gb3 accumulation is blocked upstream, providing an alternative therapeutic mechanism that addresses the limitations of direct enzyme replacement.
2Reliability
If substrate reduction therapy targeting FAPP2 is implemented, then Gb3 accumulation is reduced, but specific inhibitors are not available due to lack of high-resolution crystal structure
Solution Approach 1:
The patent performs preliminary structural characterization by determining the crystal structure of the FAPP2 GLTP domain before inhibitor development. This advance structural information reveals the binding pocket geometry and key residues (such as Trp407, Asp360, Asn364) that are critical for glycolipid recognition. By obtaining this structural data in advance, the patent lays the foundation for subsequent rational drug design and inhibitor optimization, eliminating the information gap that previously prevented FAPP2 inhibitor development.
3Reliability
If FAPP2 is targeted to reduce Gb3 synthesis, then substrate accumulation is limited, but the structural differences between FAPP2 and GLTP make inhibitor design challenging
Solution Approach 1:
The patent applies local quality analysis by focusing on the specific structural features of the FAPP2 GLTP domain that distinguish it from human GLTP. The structure reveals local differences in the binding pocket architecture, helix content, and residue composition (e.g., lower thermal stability with Tm of about 41°C compared to 53°C for GLTP). By identifying these localized structural variations, the patent enables the design of inhibitors that are specific to FAPP2 and will not cross-react with GLTP or other similar proteins, thereby simplifying the inhibitor design process through targeted structural optimization.
Data Source
AI summary
In some embodiments, the present invention provides method of identifying compounds that bind to phosphoinositol 4-phosphate adaptor protein-2 (FAPP2), including the steps of computationally identifying a compound that binds to FAPP2 using the atomic coordinates of at least the amino acids which make up the substrate binding pocket of FAPP2. Also provided are methods of designing, selecting and/or optimizing a compound that binds to FAPP2.